Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis.
Polo-like kinase 4 (PLK4), belonging to serine/threonine kinase family, is critical for centriole replication and cell cycle progression. PLK4 has been proposed as a tumor suppressor in hepatocellular carcinoma (HCC). However, its expression and significance in HCC have not been well studied. In the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3400587?pdf=render |
| _version_ | 1811330465541390336 |
|---|---|
| author | Lili Liu Chris Zhiyi Zhang Muyan Cai Jia Fu George Gong Chen Jingping Yun |
| author_facet | Lili Liu Chris Zhiyi Zhang Muyan Cai Jia Fu George Gong Chen Jingping Yun |
| author_sort | Lili Liu |
| collection | DOAJ |
| description | Polo-like kinase 4 (PLK4), belonging to serine/threonine kinase family, is critical for centriole replication and cell cycle progression. PLK4 has been proposed as a tumor suppressor in hepatocellular carcinoma (HCC). However, its expression and significance in HCC have not been well studied. In the present study, we found that PLK4 was markedly downregulated in both HCC cell lines and fresh cancer tissues, using quantitative real-time-PCR and western blot. Immunohistochemistry data also revealed that decreased expression of PLK4 was present in 72.4% (178/246) of HCC tissues, compared with the corresponding adjacent nontumorous tissues. Furthermore, PLK4 expression significantly correlated with clinicopathological parameters, including clinical stage (P=0.034), serum α-fetoprotein (AFP) (P=0.019) and tumor size (P=0.032). Moreover, HCC patients with low PLK4 expression survived shorter than those with high PLK4 expression, as indicated by overall survival (P=0.002) and disease-free survival (P=0.012) assessed by the Kaplan-Meier method. In addition, multivariate analysis suggested PLK4 as an independent predictor of overall survival (HR, 0.556; 95%CI, 0.376-0.822; P=0.003) and disease-free survival (HR, 0.547; 95%CI, 0.382-0.783; P=0.001). Collectively, our study demonstrated that PLK4 was remarkably downregulated in HCC and could be served as a potential prognostic marker for patients with this deadly disease. |
| first_indexed | 2024-04-13T16:03:33Z |
| format | Article |
| id | doaj.art-9a57b603ed194a62b6538d79fa98a792 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T16:03:33Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9a57b603ed194a62b6538d79fa98a7922022-12-22T02:40:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4129310.1371/journal.pone.0041293Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis.Lili LiuChris Zhiyi ZhangMuyan CaiJia FuGeorge Gong ChenJingping YunPolo-like kinase 4 (PLK4), belonging to serine/threonine kinase family, is critical for centriole replication and cell cycle progression. PLK4 has been proposed as a tumor suppressor in hepatocellular carcinoma (HCC). However, its expression and significance in HCC have not been well studied. In the present study, we found that PLK4 was markedly downregulated in both HCC cell lines and fresh cancer tissues, using quantitative real-time-PCR and western blot. Immunohistochemistry data also revealed that decreased expression of PLK4 was present in 72.4% (178/246) of HCC tissues, compared with the corresponding adjacent nontumorous tissues. Furthermore, PLK4 expression significantly correlated with clinicopathological parameters, including clinical stage (P=0.034), serum α-fetoprotein (AFP) (P=0.019) and tumor size (P=0.032). Moreover, HCC patients with low PLK4 expression survived shorter than those with high PLK4 expression, as indicated by overall survival (P=0.002) and disease-free survival (P=0.012) assessed by the Kaplan-Meier method. In addition, multivariate analysis suggested PLK4 as an independent predictor of overall survival (HR, 0.556; 95%CI, 0.376-0.822; P=0.003) and disease-free survival (HR, 0.547; 95%CI, 0.382-0.783; P=0.001). Collectively, our study demonstrated that PLK4 was remarkably downregulated in HCC and could be served as a potential prognostic marker for patients with this deadly disease.http://europepmc.org/articles/PMC3400587?pdf=render |
| spellingShingle | Lili Liu Chris Zhiyi Zhang Muyan Cai Jia Fu George Gong Chen Jingping Yun Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS ONE |
| title | Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. |
| title_full | Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. |
| title_fullStr | Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. |
| title_full_unstemmed | Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. |
| title_short | Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. |
| title_sort | downregulation of polo like kinase 4 in hepatocellular carcinoma associates with poor prognosis |
| url | http://europepmc.org/articles/PMC3400587?pdf=render |
| work_keys_str_mv | AT lililiu downregulationofpololikekinase4inhepatocellularcarcinomaassociateswithpoorprognosis AT chriszhiyizhang downregulationofpololikekinase4inhepatocellularcarcinomaassociateswithpoorprognosis AT muyancai downregulationofpololikekinase4inhepatocellularcarcinomaassociateswithpoorprognosis AT jiafu downregulationofpololikekinase4inhepatocellularcarcinomaassociateswithpoorprognosis AT georgegongchen downregulationofpololikekinase4inhepatocellularcarcinomaassociateswithpoorprognosis AT jingpingyun downregulationofpololikekinase4inhepatocellularcarcinomaassociateswithpoorprognosis |